bluuebunny/crossref_metadata_2025_split huggingface dataset:
Management Options and Clinical Outcomes After Flexor Tendon Ruptures Following Volar Plating of Distal Radius Fractures
Authors: Langdell Hannah C. , Emovon Emmanuel O. , Hammert Warren C. 
Published: November 2024

Background: The transition to volar locking plates for the treatment of distal radius fractures has improved patients’ range of motion, reduced extensor tendon issues, and hastened return to activity compared to older fixation methods or nonoperative treatment. One drawback to volar plating is the potential for flexor tendon ruptures due to aberrant plate or screw placement. This study aims to describe the reconstruction options and patient outcomes after flexor tendon rupture due to volar plating. Methods: This is a single-institution, retrospective review of patients who presented with flexor tendon rupture from 2014 to 2023 after a distal radius fracture previously managed with a volar plate. Patient demographics, operative details, range of motion, complications, and patient-reported outcomes were collected. Results: Ten patients presented with flexor tendon ruptures after volar plating for distal radius fractures from 2014 to 2023. The most common rupture was flexor pollicis longus (FPL) in 7 patients, followed by index finger flexor digitorum profundus (FDP) in 2 patients, and small and ring finger FDP rupture in 1 patient. Flexor pollicis longus (FPL) was reconstructed with a palmaris longus (PL) graft in 4 patients, ring finger flexor digitorum superficialis transfer in 2 patients, and repaired primarily in 1 patient. All patients with FPL ruptures regained functional thumb interphalangeal flexion except for 1 patient who reruptured 4 weeks after surgery. Conclusions: Flexor tendon ruptures can occur following volar plating of distal radius fractures, even years after fixation of the fracture. These are attritional ruptures and generally reconstructed with tendon grafting of transfer, providing functional flexion of the affected digit.
Accelerated aspiration with Q™ catheter: An in vitro study
Authors: Reymond Philippe , Contreras Mayra , Brina Olivier , Langston Trent , Chesler Naomi , Brinjikji Waleed , Wainwright John , Machi Paolo 
Published: November 2024

Background and Purpose Thrombectomy in distal, medium vessels is a topic of increasing interest. To date, there are few in vitro studies focused on performance of ≤5F catheters in medium vessels. The purpose of this study is to compare the performance of the 3F, 4F, and 5F MIVI Neuroscience Q Catheters versus Penumbra 3F, 4F, and MicroVention Sofia 5F Catheters. Methods Using in vitro methods, we assessed and compared the following parameters: aspiration flow rates, clot uncorking forces, impulse, and clot ingestion. For flow rate, each aspiration catheter was immersed in a cylindrical container. Flow rate at one second was used to calculate impulse. For clot uncorking force, the force required to disengage a catheter from a simulated clot was recorded. For ingestion, we measured time to ingest soft and medium stiffness synthetic clots. Results The measured flow rates without a stent retriever for the Q3, Q4, and Q5 catheters were 3.54 ml/s, 5.32 ml/s, and 6.87 ml/s. The measured flow rates without a stent retriever for the 3MAX, 4MAX, and 5F Sofia were 1.46 ml/s, 2.56 ml/s, and 1.73 ml/s. The impulse calculated for one second was 26 mNs for Q5 vs 9 mNs for Sofia 5, 35 mNs for Q4 vs 15 mNs for 4Max< and 35 mNs for Q3 vs 9 mNs for 3Max. The average system ingestion for Q was significantly faster than the competitive catheters. Conclusions The Q catheters demonstrated higher flow rates, higher uncorking force, and faster complete clot ingestion than competitive catheters.
Multifidus Degeneration: The Key Imaging Predictor of Adjacent Segment Disease
Authors: Burkhard Marco D. , Chiapparelli Erika , Hambrecht Jan , Köhli Paul , Guven Ali E. , Tsuchiya Koki , Schönnagel Lukas , Caffard Thomas , Amoroso Krizia , Altorfer Franziska C. S. , Evangelisti Gisberto , Zhu Jiaqi , Shue Jennifer , Kelly Michael J. , Girardi Federico P. , Cammisa Frank P. , Sama Andrew A. , Hughes Alexander P. 
Published: November 2024

Study Design Retrospective cohort study. Objectives To identify imaging predictors on pre- and perioperative imaging that are associated with a future revision surgery for adjacent segment disease (ASD) following lumbar fusion. Methods Patients undergoing open posterior lumbar fusion between 2014-2022 were followed-up for >2-year. The initial MRI was evaluated for disc degeneration by Pfirrmann (grade 1-5); Modic changes (0-3); as well as fatty infiltration and functional cross-sectional area (fCSA) of the multifidus, erector spinae, and psoas. Spinopelvic alignment was measured pre- and postoperatively. Results Of 216 patients, 14.8% (n = 32) required revision surgery for ASD in the further course. There were no significant differences in Modic changes or Pfirrmann grades between the ASD group and controls. Fatty infiltration was significantly higher in the ASD group for both the erector spinae (40.5% vs 36.9%, P = 0.043) and multifidus muscles (61.0% vs 53.9%, P = 0.003). Additionally, the multifidus fCSA was smaller in patients who developed ASD (5.7 cm2 vs 6.7 cm2). Pre- and postoperative spinopelvic parameters were not significantly different between groups, and no other MRI measurements showed a significant difference. In a multivariable logistic regression model adjusting for age and sex, multifidus fatty infiltration emerged as the only significant predictor of ASD revision surgery ( P = 0.004). Patients with more than 58% multifidus fatty infiltration had over double the risk of developing ASD (OR 2.7, 95% CI: 1.1-6.5, P = 0.032). Conclusions Multifidus fatty infiltration is the key imaging predictor for the development of ASD requiring surgical revision. Disc degeneration and spinopelvic alignment appear to have less impact.
Using the Health Belief Model to Predict Self-Care Behaviors Among Patients With Cardiovascular Disease Post COVID-19 Pandemic: A Perspective From the United Arab Emirates
Authors: Mosleh Sultan M. , Khraisat Adam , Shoqirat Noordeen , Obeidat Rana 
Published: November 2024

Introduction Data on how the health belief model constructs might predict the self-care behavior of patients with cardiovascular disease (CVD) post-coronavirus disease (COVID-19) 2019 pandemic are scarce. Objective This study determines the predictors influencing patients’ intention to adhere to self-care for CVD in the United Arab Emirates after the COVID-19 pandemic. Methods A descriptive cross-sectional design was used. A total of 222 patients with CVD were purposively selected. Three scales were used: Health Beliefs Related to Cardiovascular Disease, Physical Activity Measurement, and Behavioral Intention Measurement. Various socio-demographic and clinical characteristics and the participants’ health belief components were considered potential factors in the multivariate analysis to identify the independent predictors of the intention of self-care behaviors. Results The participants had a high level of perceived CVD risk (M = 4.02, SD = 0.714) and high level of perceived benefits regarding adopting healthy behavior (M = 4.30, SD = 0.817). The multiple linear regression revealed that not performing regular sweating exercises (β = 0.230), not receiving smoking cessation instructions (β = 0.214, p = .005), being sufficiently active (β = 0.304), and having no history of heart surgery (β = 0.155) were the independent predictors of low intention scores. The perceived benefits and perceived cues to the action of the Health Belief Model (HBM) were significant independent predictors of behavior intention and were responsible for a 22% increase in the participants’ intention variances . Conclusions In a post-COVID CVD, this investigation delineated perceived benefits and cues to action derived from the HBM as the most robust prognosticators of behavioral intention (accounting for 47% of the variance), superseding sociodemographic and clinical parameters (explaining 25% of the variance). These results advocate for tailored interventions accentuating individual advantages and explicit prompts for behavioral modifications within this demographic.
Design of CONQUEST, a novel, randomized, placebo-controlled, Phase 2b platform clinical trial to investigate new treatments for patients with early active systemic sclerosis with interstitial lung disease
Authors: Khanna Dinesh , Evnin Luke B , Assassi Shervin , Benton Wade W , Gordon Gregory , Maslova Karina , Steffgen Juergen , Maher Toby M 
Published: November 2024

Objective: Safe, effective therapies are urgently needed for patients with systemic sclerosis. However, clinical trial recruitment is challenging given the limited number of people with systemic sclerosis and further restrictions imposed by eligibility criteria. Innovative approaches are needed to accelerate development of new therapies. This article describes the rationale and trial design for CONQUEST (NCT06195072), a novel platform clinical trial sponsored by the Scleroderma Research Foundation, a not-for-profit organization. Methods: CONQUEST is a multicentre, double-blind, randomized, placebo-controlled, Phase 2b platform trial evaluating the efficacy, safety and pharmacodynamics of multiple investigational products to treat early active systemic sclerosis with interstitial lung disease versus placebo. The primary objective is to evaluate change from baseline to Week 52 in forced vital capacity (mL). Secondary objectives include evaluating changes from baseline to Week 52 in high-resolution computed-tomography-assessed lung involvement and dyspnoea, and overall treatment response (measured using the revised composite response index in diffuse systemic sclerosis score in participants with diffuse cutaneous systemic sclerosis). Results: Patients will be enrolled across more than 150 centres in over 25 countries. Recruitment started on 15 April 2024. Conclusion: As the first platform clinical trial in the rheumatology field, CONQUEST aims to meaningfully accelerate the development of new therapies for early active systemic sclerosis. Depending on regimen-specific results, trial data could be used to plan and design a Phase 3 trial or may be used alone or together with another registrational trial to establish substantial evidence of effectiveness and safety. The first molecules to be studied, amlitelimab and nerandomilast, both have a strong scientific rationale to modify underlying disease processes in systemic sclerosis. ClinicalTrials.gov: Platform Clinical Study for Conquering Scleroderma (CONQUEST); NCT06195072; https://www.clinicaltrials.gov/study/NCT06195072
Headache disorders and risk of stroke: A register-linked HUNT study
Authors: Giri Samita , Tronvik Erling , Dalen Håvard , Ellekjær Hanne , Olsen Alexander , Hagen Knut 
Published: November 2024

Background Many studies have found that migraine with aura (MA) is a risk factor of stroke, but the relationship between stroke and migraine without aura and tension-type headache is unclear. The aim of this study was to investigate whether primary headache disorders, including subtypes of migraine, increase the risk of ischemic or hemorrhagic stroke. Methods This large population-based 13-year follow-up study used baseline headache data from the third Trøndelag Health Study (HUNT3) performed between 2006 and 2008. The HUNT3 headache data were linked to the Norwegian National Stroke Register that includes stroke diagnoses recorded from 2013 until December 2021. The association between stroke and headache status was investigated in individuals aged ≥20 years without stroke at baseline. Prospective associations were evaluated using multivariable Cox proportional hazard models with 95% confidence intervals. Separate sub-group analyses by age and sex were performed. Results Among 37,364 included participants, 50% were younger than 55 years. A total of 1095 (2.9%) developed stroke after a median of 9 years. In the multi-adjusted model, reporting MA at baseline was associated with increased risk of stroke at follow-up (HR 1.59, 95% CI 1.14–2.21) compared with those without headache. The increased risk of stroke was most evident among individuals <55 years with MA (HR 2.18, 95% CI 1.24–3.82) and among women (HR 1.70, 95% CI 1.12–2.59). Migraine without aura (MO), tension-type headache (TTH) and unclassified headaches were not associated with increased risk of stroke. Conclusions During 15 years of follow-up, individuals with MA were more likely to suffer from stroke compared to those without headache. The relationship with MA was even stronger in women, and for young individuals aged <55 years. Individuals with MO or TTH were not associated with increased risk of stroke.
“Frontal Sinus Setback in Facial Feminization Surgery: Emphasizing Anatomical Landmarks Over Virtual Planning and Cutting Guides”
Authors: Xu Hannah , Benedict Michelle D. , Yousif Sabrina , Prescher Hannes , Vercler Christian J. 
Published: November 2024

Background: Demand for facial feminization surgery (FFS) is growing amidst increasing recognition of its significant impact on gender affirmation. Forehead contouring via frontal sinus setback is a powerful procedure for feminizing the upper facial skeleton. While Virtual Surgical Planning (VSP) has been described as a useful tool in these surgeries, the associated cost may limit access for patients seeking these transformative interventions, especially those who lack insurance coverage for FFS. This study challenges the emerging notion that VSP is critical for the successful execution of frontal sinus setbacks. Methods: We present a technique that relies on well-defined anatomical landmarks of the frontal sinus and standard maxillofacial CT imaging for pre-operative planning, eliminating the need for expensive, pre-operatively prepared cutting guides. Key steps in this technique include obtaining detailed measurements of the frontal sinus dimensions and contour, visualizing the nasofrontal junction, reshaping the frontal sinus, resecting the corrugator muscle, and finally, performing a direct browlift. Results: In our cohort of 13 patients, including a 65-year-old transgender female with significant forehead prominence, this approach consistently achieved satisfactory outcomes without complications. Conclusion: By demonstrating that high-quality results can be achieved without VSP, we present a cost-conscious approach to FFS for a more inclusive and equitable provision to gender-affirming care. Surgical expertise and understanding of patient-specific anatomy are crucial in achieving these results, emphasizing the importance of skill over reliance on technology.
Rapidly Developing and Elusive Rhino-Orbital-Cerebral Mucormycosis
Authors: Durstock Nicholas F. , Williams Kevin M. , Saeed Omar B. , Warwar Ronald E. 
Published: November 2024

Purpose: To report a case of rapidly progressing rhino-orbital cerebral mucormycosis that was particularly difficult to diagnose, initially presenting as orbital apex syndrome. Major findings: In this case, a 59-year-old male patient with uncontrolled diabetes presented with a history of facial pain with no ocular involvement. Within 1 day of hospitalization, the patient developed complete ophthalmoplegia and total visual impairment of the right eye. Over the course of 2 hospital stays, several biopsies resulted in no significant histopathological findings, and several cultures resulted in growth of only a single colony of rhizopus mucor from the sinonasal mucosa. Given the high clinical suspicion of an invasive fungal infection, a universal PCR test was performed from a rapidly developing abscess in the frontal lobe and confirmed a diagnosis of mucormycosis. Conclusions: Orbital apex syndrome is a significant diagnosis that can be caused by a variety of factors, including those of fungal, bacterial, neoplastic, or inflammatory origin. Fungal infections, are a particularly concerning cause of orbital apex syndrome, given their ability to penetrate in and through the orbit to the brain, often resulting in an alarmingly high mortality rate. Mucormycosis, specifically rhino-orbital cerebral mucormycosis, is a very severe opportunistic invasive fungal infection, most often afflicting the immunocompromised. A clinician must be very thorough in their workup so as to not miss such a devastating diagnosis. Histopathology and cell cultures are currently the gold standard for diagnosis, with the potential to augment their technical success through the use of molecular techniques, such as universal PCR.
Real-World Comparison of Oral Versus Injectable Semaglutide for the Reduction of Hemoglobin A1C and Weight in Patients with Type 2 Diabetes
Authors: Pinto Maria , Brennan Lillian , Diehl Katie , Lin Shally , Heacock Samantha 
Published: November 2024

Background: No head-to-head comparisons of semaglutide formulations currently exist in the literature. In practice, many may think that oral and injectable semaglutide formulations are interchangeable, although there is currently limited real-world data to determine whether this is accurate. Objective: The purpose of this study was to determine the effect of oral versus injectable semaglutide on hemoglobin A1C (HbA1C) and weight in patients with type 2 diabetes (T2D). Methods: This was a retrospective single-center review of adult patients who had a diagnosis of T2D and were treated with oral or injectable semaglutide between November 1, 2019, and July 31, 2022. Primary outcome was a comparison of changes in HbA1C (%) and weight (kg) from baseline to 6 months between patients receiving oral versus injectable semaglutide, stratified according to highest dose received. Secondary outcomes included frequency of dose reductions and discontinuations, achievement of clinical goals, and presence of an embedded clinical pharmacist at patients’ primary care office. Results: A total of 105 patients were included. Patients experienced mean decreases in HbA1C and weight from baseline to 6 months of −1.75% ( P < 0.001) and −3.64 kg ( P = 0.015), respectively, in the oral semaglutide group and −1.35% ( P < 0.001) and −5.26 kg ( P < 0.001), respectively, in the injectable semaglutide group. When directly comparing semaglutide formulations, oral semaglutide demonstrated a 0.4% greater numerical reduction in HbA1C ( P = 0.523) and injectable semaglutide demonstrated a 1.62-kg greater numerical reduction in weight ( P = 0.312). Adverse events (AEs) occurred more frequently with oral semaglutide than with injectable semaglutide (16.7% vs 4.9%). Discontinuation due to AEs was more common with oral semaglutide. Conclusion: In this study, patients with T2D who received oral semaglutide demonstrated greater reductions in HbA1C, whereas those treated with injectable semaglutide had greater reductions in weight, although there were no statistically significant reductions in HbA1C or weight between the 2 formulations. Rates of AEs and discontinuation were more common in the oral semaglutide group.
Three new members of the hakite series, Cu6(Cu4Me2+2)Sb4Se13: hakite-(Cd), hakite-(Fe) and hakite-(Zn) from the Bytíz deposit, uranium and base-metal Příbram ore district, Czech Republic
Authors: Sejkora Jiří , Biagioni Cristian , Škácha Pavel , Musetti Silvia , Dolníček Zdeněk 
Published: November 2024

AbstractHakite-(Cd), hakite-(Fe) and hakite-(Zn) are new minerals belonging to the tetrahedrite group and forming, along with hakite-(Hg), the hakite series. They have been discovered in samples collected from the Bytíz deposit, in the uranium and base-metal Příbram ore district, Central Bohemia, Czech Republic. They occur as anhedral grains, up to 300 μm in size, in a calcite gangue, associated with clausthalite, cadmoselite, hakite-(Hg) [for hakite-(Cd)], berzelianite, bukovite, bytízite, crookesite, chaméanite, eskebornite, příbramite, the not yet approved giraudite-(Hg) and giraudite-(Cu), hakite-(Hg), umangite, chalcopyrite, tetrahedrite-(Zn) and a new Cu–As selenide [for hakite-(Fe) and -(Zn)]. The three new species are black, with a metallic lustre. Mohs hardness is ca. 3½–4; calculated density is 6.019 (Hak-Cd), 6.011 (Hak-Fe) and 6.081 g.cm–3 (Hak-Zn). In reflected light, they are isotropic, pale grey with bluish (Hak-Cd) or brownish (Hak-Fe and Hak-Zn) shades. Empirical formulae of hakite-(Cd), hakite-(Fe), and hakite-(Zn) are Cu9.71Ag0.24Cd1.51Hg0.43Zn0.03(Sb3.94As0.13)Σ4.07Se11.35S1.57, Cu10.11Ag0.18Fe0.81Zn0.50Hg0.26(Sb3.72As0.41)Σ4.13Se12.65S0.12, and Cu10.03Ag0.24Zn0.61Fe0.53Hg0.45(Sb3.55As0.60)Σ4.15Se12.82S0.08, respectively. These formulae correspond to the end-member formulae Cu6(Cu4Cd2)Sb4Se13 (Hak-Cd), Cu6(Cu4Fe2)Sb4Se13 (Hak-Fe), and Cu6(Cu4Zn2)Sb4Se13 (Hak-Zn). All these new members of the hakite series are cubic, I$\bar{4}$3m, Z = 2, with unit-cell parameters a = 10.8860(6) Å, V = 1290.0(2) Å3 (Hak-Cd); a = 10.7983(4) Å, V = 1259.12(14) Å3 (Hak-Fe); and a = 10.8116(14) Å, V = 1263.8(5) Å3 (Hak-Zn). These species are isotypic with the other members of the tetrahedrite group, and their crystal structures have been refined on the basis of single-crystal X-ray diffraction data down to R1 values of 0.0230 (Hak-Cd), 0.0254 (Hak-Fe), and 0.0302 (Hak-Zn). These structural data allow us to describe the S-to-Se partitioning in hakite-series minerals and to understand the mechanisms avoiding too short Me–Se distances in these selenides.